Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

Eloralintide vs Retatrutide: Amylin (AMY1R) vs Triple Agonist — Research Comparison

By SaiyanMed Research Team · Updated 4 November 2026 · For in-vitro research use only

Quick answer

Eloralintide (LY3841136) and retatrutide (LY3437943) are two different investigational peptides from Eli Lilly. Eloralintide is a selective amylin-receptor agonist designed to prefer human AMY1R over AMY3R and CTR in recombinant cell assays.[1] Retatrutide is a unimolecular agonist of the GIP, GLP-1 and glucagon receptors.[2][3] Published weight-change percentages come from separate placebo-controlled trials with different durations, populations, dose schedules and estimands. No head-to-head human trial of eloralintide versus retatrutide was identified as of 4 November 2026. This page is mechanism and trial-literacy education for laboratory identity work — not a ranking of “which is better for weight loss,” and not medical advice.

Key takeaways

  • Different receptor systems. Amylin (AMY1R-preferring) versus GIPR / GLP-1R / GCGR triple agonism — complementary pipeline hypotheses, not “upgrade versions” of each other.[1][2]
  • Different development codes. LY3841136 ≠ LY3437943. Match the LY code, CAS and MS/HPLC identity on any research COA.
  • Evidence map, not scoreboard. Eloralintide Phase 2 (Lancet; NCT06230523; 48 weeks) versus retatrutide Phase 2 (NEJM; NCT04881760; 48 weeks) versus retatrutide Phase 3 TRIUMPH-1 (NEJM; NCT05929066; 80 weeks).[4][3][5]
  • Estimands matter. Efficacy estimand ≠ treatment-regimen estimand. Cross-trial % weight change is descriptive only.
  • Same-target comparison lives elsewhere. For amylin-neighbourhood chemistry, see eloralintide vs cagrilintide.
  • RUO only. SaiyanMed materials are research-grade supply context. Not for human or veterinary use; not FDA-approved therapy substitutes.

Contents

  1. Identity card: codes, receptors, status
  2. Receptor biology (RUO lens)
  3. Evidence map (separate trials)
  4. Why cross-trial % weight change is not a ranking
  5. Published adverse-event patterns (literature facts)
  6. Related comparison: amylin vs amylin
  7. Laboratory identity checks and COA
  8. Glossary
  9. FAQ
  10. Research Use Only Disclaimer
  11. References

Identity card: codes, receptors, status

Property Eloralintide Retatrutide Source
Common name Eloralintide Retatrutide [1][3]
Developer code LY3841136 LY3437943 [1][2]
CAS (registry) 2883634-40-8 2381089-83-2 [6][7]
Pharmacologic class Selective / AMY1R-preferring amylin receptor agonist Unimolecular GIP / GLP-1 / glucagon receptor agonist [1][2]
Primary receptor framing in papers Human AMY1R preferential vs AMY3R and CTR (assay-bound fold differences) GIPR, GLP-1R and GCGR; discovery abstract: balanced GCGR and GLP-1R activity with relatively more GIPR activity [1][2]
Studied clinical interval Once-weekly subcutaneous (investigational) Once-weekly subcutaneous (investigational) [4][3]
Lead peer-reviewed obesity evidence (as of 4 Nov 2026) Phase 2, 48 weeks (Lancet) Phase 2, 48 weeks (NEJM) + Phase 3 TRIUMPH-1, 80 weeks (NEJM) [4][3][5]
Regulatory status Investigational; Phase 3 ENLIGHTEN programme recruiting (e.g. NCT07321886) Investigational; Phase 3 TRIUMPH programme with peer-reviewed TRIUMPH-1 report [8][5]
Same molecule? No. Different sequences, receptor systems and LY codes. —

Research-supply pages for identity and COA context: Eloralintide peptide (LY3841136) · Retatrutide peptide (LY3437943). Background primer: What is eloralintide?

Receptor biology (RUO lens)

Eloralintide — amylin / AMY1R preference

Amylin receptors are calcitonin-receptor (CTR) cores paired with receptor activity-modifying proteins (RAMPs). In Lilly’s discovery / translational paper (PMC12640043; PMID 41109426), eloralintide preferentially activated human AMY1R — approximately 12-fold more potent than human CTR and approximately 11-fold more potent than human AMY3R in cAMP assays under the reported conditions.[1] Those fold differences are assay-bound (cell background, albumin conditions, readout). In rats, the selectivity pattern differed: both AMY1R and AMY3R were activated more potently than CTR.[1] Preclinical work also reported less conditioned taste avoidance than non-selective cagrilintide in lean rats, and body-weight change in DIO rats driven primarily by fat-mass loss.[1] Those animal findings are mechanism context for research design — not clinical predictions.

Structurally, the same paper describes a 37-residue amylin-analogue backbone with a methylene thioacetal bridge replacing the native disulfide and a C20 fatty-diacid conjugation (albumin-binding half-life handle) supporting once-weekly pharmacokinetics in animals and a human Phase 1 single-ascending-dose study (NCT05295940).[1][9]

Retatrutide — unimolecular triple agonism

Retatrutide (LY3437943) was engineered as a single peptide that activates GCGR, GIPR and GLP-1R. The discovery abstract (Coskun et al., Cell Metabolism, PMID 35985340) states that in vitro LY3437943 shows balanced GCGR and GLP-1R activity but more GIPR activity, that obese-mouse body-weight loss was augmented by GCGR-mediated energy-expenditure increases added to GIPR- and GLP-1R-driven intake reduction, and that Phase 1 pharmacokinetics supported once-weekly dosing.[2] Exact numeric EC50 / fold tables from the full PDF were not re-verified end-to-end in this draft (publisher PDF gate); do not treat secondary “X-fold vs native ligand” charts as authoritative unless you open the paper yourself. The NEJM Phase 2 obesity paper summarises the clinical pharmacology as a triple-hormone-receptor agonist of GIP, GLP-1 and glucagon receptors.[3]

Why both programmes can run in parallel

Amylin satiety signalling and incretin-plus-glucagon polypharmacology are different biological hypotheses. Running both does not imply that one molecule “replaces” the other. Combination research that pairs eloralintide with tirzepatide (e.g. NCT06603571) is a separate question from retatrutide monotherapy and is not evidence for an eloralintide–retatrutide blend.[10]

Evidence map (separate trials)

Read each row as its own experiment. Columns are aligned for literacy, not for declaring a winner.

Programme Registry / paper Population (high level) Duration Selected published weight result Estimand / analysis note
Eloralintide Phase 2 NCT06230523; Billings et al., Lancet 2025 (PMID 41207310) 263 adults; obesity or overweight + comorbidity; without type 2 diabetes; 46 U.S. centres 48 weeks Lancet abstract efficacy estimand: mean % change ≈ −9% (1 mg), −12% (3 mg), −18% (6 mg), −20% (9 mg), −20% (6–9 mg), −16% (3–9 mg) vs −0.4% placebo Primary: % body-weight change at week 48; efficacy estimand labelled in abstract[4][11]
Eloralintide discovery / Phase 1 PMC12640043; NCT05295940 Healthy participants, single ascending doses 0.04–12 mg (n=48 in reported Phase 1) Single dose; week-4 weight exploratory Week-4 mean % change −2.5% (4 mg) and −4.4% (12 mg) vs placebo +0.6% Early PoC / PK–PD; not Phase 2 efficacy[1]
Retatrutide Phase 2 NCT04881760; Jastreboff et al., NEJM 2023 (PMID 37366315) 338 adults; BMI ≥30 or ≥27 with condition; diabetes excluded 48 weeks (primary endpoint at 24 weeks) LS-mean % change at 48 weeks: −8.7% (1 mg), −17.1% (combined 4 mg), −22.8% (combined 8 mg), −24.2% (12 mg) vs −2.1% placebo; at 24 weeks up to −17.5% (12 mg) vs −1.6% Primary = week 24; week 48 is secondary[3][12]
Retatrutide Phase 3 TRIUMPH-1 NCT05929066; Jastreboff et al., NEJM 2026 (DOI 10.1056/NEJMoa2604169) 2,339 randomised adults with obesity without diabetes; nested OA / OSA subgroups 80 weeks Mean % change (treatment-regimen / ITT framing in abstract): −17.6% (4 mg), −23.7% (9 mg), −25.0% (12 mg) vs −3.9% placebo Weight endpoints handled with treatment-regimen estimand per methods abstract; longer and larger than either Phase 2[5][13]

One-decimal precision note (eloralintide Phase 2): contemporaneous secondary coverage of the same Lancet publication (e.g. Healio / ObesityWeek reporting) cites efficacy-estimand means such as −9.5% / −12.4% / −17.6% / −20.1% / −19.9% / −16.4% and also lists a treatment-regimen estimand series (e.g. −17.5% at 9 mg vs −2.3% placebo).[14] Prefer the peer-reviewed Lancet text for citation; treat secondary one-decimal tables as corroboration until your team holds the full PDF.

Pending / not asserted here: some secondary articles quote a TRIUMPH-1 efficacy estimand near −28% at 12 mg. The peer-reviewed NEJM TRIUMPH-1 abstract we used for this draft emphasises the treatment-regimen figures above. Until the full paper’s efficacy-estimand table is read end-to-end, that secondary figure is not used as a ranking input on this page.

Why cross-trial % weight change is not a ranking

  1. No shared randomisation. Participants were never assigned eloralintide vs retatrutide in one protocol.
  2. Time base differs. 48-week Phase 2 rows are not interchangeable with an 80-week Phase 3 row.
  3. Estimands differ. An efficacy estimand answers a hypothetical “if everyone stayed on assigned study treatment” question; a treatment-regimen estimand answers an intention-to-treat-style question that keeps post-discontinuation outcomes in view. Both can be “correct” and still not comparable across products.[4][5]
  4. Placebo arms differ. Example: eloralintide Phase 2 placebo ≈ −0.4% (efficacy estimand abstract) vs retatrutide Phase 2 placebo −2.1% at 48 weeks — another reason subtraction is invalid.[4][3]
  5. Dose and titration differ. Arm labels (mg) identify research groups; they are not prescribing instructions and are not interchangeable across molecules.
  6. Stage differs. Retatrutide currently has a larger, later-stage peer-reviewed obesity dataset; that is a statement about evidence maturity, not a measured comparative treatment effect.

Published adverse-event patterns (literature facts)

Report patterns as published. Do not translate them into “better GI” marketing.

  • Eloralintide Phase 2 (Lancet abstract): most common AEs included nausea (11%–64% across eloralintide arms vs 14% placebo) and fatigue (0%–46% vs 12% placebo), with rates varying by dose / escalation arm.[4]
  • Retatrutide Phase 2 (NEJM): gastrointestinal AEs were most common, dose-related, mostly mild to moderate, and partially mitigated with a lower starting dose (2 mg vs 4 mg); dose-dependent heart-rate increases peaked at 24 weeks and declined thereafter.[3]
  • Retatrutide TRIUMPH-1 (NEJM abstract): most common adverse events were gastrointestinal; the abstract also frames nested osteoarthritis pain and sleep-apnea endpoints that are outside this comparison’s scope.[5]

Placebo-controlled monotherapy trials cannot establish comparative safety between eloralintide and retatrutide.

If the research question is “two amylin-pathway analogues — how do structure, selectivity and MS identity differ?”, use the same-neighbourhood page: Eloralintide vs cagrilintide. That article owns ring chemistry, lipid position and calculated mass gaps. This article owns different receptor systems (amylin vs triple agonist) and trial-literacy rules. Cross-link both; do not let them cannibalise each other.

Laboratory identity checks and COA

Clinical trial drug product ≠ research vial. For RUO procurement and analytical identity:

  • Confirm the LY code and common name on the label and COA (LY3841136 vs LY3437943).
  • Match CAS where provided (2883634-40-8 vs 2381089-83-2).
  • Require lot-linked HPLC purity and MS (intact mass / expected m/z) consistent with the declared sequence / salt form.
  • Treat “GLP-3” marketing slang as non-scientific; retatrutide’s peer-reviewed framing is GIP/GLP-1/glucagon triple agonism.[3]
  • Read COAs with a checklist mindset: How to read a peptide COA.

Product pages (research-grade context only): buy / view Eloralintide RUO · buy / view Retatrutide RUO.

Glossary

  • AMY1R / AMY3R: amylin receptors formed by CTR plus RAMP1 or RAMP3.
  • CTR: calcitonin receptor.
  • GIPR / GLP-1R / GCGR: receptors for GIP, GLP-1 and glucagon.
  • Triple agonist / unimolecular polyagonist: one peptide engineered to activate multiple receptors.
  • Estimand: the precise definition of the treatment effect a trial estimates (e.g. efficacy vs treatment-regimen).
  • Efficacy estimand: typically estimates effects under hypothetical full adherence to assigned study treatment (definitions vary by protocol).
  • Treatment-regimen estimand: typically an ITT-style estimate that incorporates intercurrent events such as discontinuation.
  • RUO: research use only — not for human or veterinary administration.
  • COA: certificate of analysis for a specific lot.

Frequently asked questions

Is eloralintide the same as retatrutide?

No. Eloralintide (LY3841136) is an AMY1R-preferring amylin receptor agonist. Retatrutide (LY3437943) is a GIP/GLP-1/glucagon triple agonist. They are different molecules with different clinical programmes.[1][3]

What do LY3841136 and LY3437943 refer to?

They are Eli Lilly development codes: LY3841136 = eloralintide; LY3437943 = retatrutide. Use the code when matching literature, registries and COAs.[1][2]

Has any trial compared them head-to-head?

No published human head-to-head randomised comparison of eloralintide versus retatrutide was identified for this draft (checked 4 November 2026). Separate placebo-controlled results cannot measure the effect of replacing one with the other.

Does a higher % weight-loss number mean retatrutide “wins”?

No. Later-stage, longer trials can report larger average reductions without creating a comparative efficacy estimate. Duration, estimand, population and dose schedule all differ. See the reading rules above.

Is eloralintide a GLP-1 drug?

No. Peer-reviewed framing places it in the amylin / AMY1R-preferring class. Combination studies that add tirzepatide are a different research question.[1][10]

What does RUO mean for these materials?

Research use only. SaiyanMed products discussed here are for in-vitro laboratory research. They are not medicines, not for compounding into treatments, and not for human or animal use. Clinical percentages are literature context only.

Are either approved by the FDA?

As of 4 November 2026, neither eloralintide nor retatrutide is an FDA-approved therapy based on the peer-reviewed and registry sources cited here. Both remain investigational.

Research Use Only Disclaimer

This article is for laboratory and analytical education only. All SaiyanMed products are sold strictly for in-vitro research use only (RUO). They are not drugs, foods, supplements or cosmetics and are not for human or animal use. Nothing here is medical advice, a dosing or reconstitution protocol, compounding guidance, clinic advice, or a recommendation to purchase for human use. Clinical-trial results are summarised as published findings from sponsor-run studies for scientific context only. Eloralintide and retatrutide are investigational and not approved by the FDA or any other regulator as of the date of this article.

{
“@context”: “https://schema.org”,
“@type”: “FAQPage”,
“@id”: “https://saiyanmed.com/eloralintide-vs-retatrutide/#faq”,
“mainEntity”: [
{
“@type”: “Question”,
“name”: “Is eloralintide the same as retatrutide?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “No. Eloralintide (LY3841136) is an AMY1R-preferring amylin receptor agonist. Retatrutide (LY3437943) is a GIP/GLP-1/glucagon triple agonist. They are different molecules with different clinical programmes.”
}
},
{
“@type”: “Question”,
“name”: “What do LY3841136 and LY3437943 refer to?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “They are Eli Lilly development codes: LY3841136 means eloralintide; LY3437943 means retatrutide. Match the code on literature, trial registries and research COAs.”
}
},
{
“@type”: “Question”,
“name”: “Has any trial compared eloralintide and retatrutide head-to-head?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “No published human head-to-head randomised comparison was identified as of 4 November 2026. Separate placebo-controlled percentages are not a ranking.”
}
},
{
“@type”: “Question”,
“name”: “Does a higher percent weight-loss number mean retatrutide wins?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “No. Trials differ in duration, estimand, population and dose schedule. Cross-trial subtraction does not measure comparative effectiveness.”
}
},
{
“@type”: “Question”,
“name”: “Is eloralintide a GLP-1 drug?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “No. Peer-reviewed framing places eloralintide in the selective amylin / AMY1R-preferring class, not as a GLP-1 receptor agonist.”
}
},
{
“@type”: “Question”,
“name”: “What does RUO mean for these materials?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Research use only. Materials are for in-vitro laboratory research, not for human or veterinary use, and are not approved therapies.”
}
},
{
“@type”: “Question”,
“name”: “Are eloralintide or retatrutide FDA approved?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “As of 4 November 2026, both remain investigational and are not FDA-approved therapies based on the sources cited in this article.”
}
}
]
}

References

  1. Briere et al. / Lilly discovery team. Eloralintide (LY3841136), a novel amylin receptor agonist… From discovery to clinical proof of concept. Molecular Metabolism. PMID 41109426; PMC12640043. https://doi.org/10.1016/j.molmet.2025.102271 · PMC full text
  2. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist… From discovery to clinical proof of concept. Cell Metabolism. 2022. PMID 35985340. https://doi.org/10.1016/j.cmet.2022.07.013 (abstract verified; full PDF gated in this draft session)
  3. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526. PMID 37366315. https://doi.org/10.1056/NEJMoa2301972
  4. Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2… trial. The Lancet. 2025. PMID 41207310. https://doi.org/10.1016/S0140-6736(25)02155-5 · PubMed
  5. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. Published 29 Sep 2026. DOI 10.1056/NEJMoa2604169. https://doi.org/10.1056/NEJMoa2604169
  6. KEGG Drug D12886 (eloralintide identity fields). https://www.kegg.jp/entry/D12886
  7. PubChem compound record: Retatrutide (CAS 2381089-83-2). https://pubchem.ncbi.nlm.nih.gov/compound/Retatrutide
  8. ClinicalTrials.gov NCT07321886 (ENLIGHTEN-1). https://clinicaltrials.gov/study/NCT07321886
  9. ClinicalTrials.gov NCT05295940 (eloralintide Phase 1 SAD). https://clinicaltrials.gov/study/NCT05295940
  10. ClinicalTrials.gov NCT06603571 (eloralintide ± tirzepatide — not retatrutide). https://clinicaltrials.gov/study/NCT06603571
  11. ClinicalTrials.gov NCT06230523 (eloralintide Phase 2). https://clinicaltrials.gov/study/NCT06230523
  12. ClinicalTrials.gov NCT04881760 (retatrutide Phase 2). https://clinicaltrials.gov/study/NCT04881760
  13. ClinicalTrials.gov NCT05929066 (TRIUMPH-1). https://clinicaltrials.gov/study/NCT05929066
  14. Healio secondary report of Billings et al. Lancet Phase 2 (one-decimal / treatment-regimen tables). 6 Nov 2025. Healio article

Related reading

Related: Grey-market pairing of retatrutide with MOTS-c is mechanism folklore, not a co-administered evidence base—see our Retatrutide + MOTS-c stack evidence map (PubMed combo gap, CB4211 ≠ native MOTS-c, identity/COA checks; RUO only).